• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Applied Genetic Technologies Corporation (Amendment)

    2/14/22 6:17:31 AM ET
    $AGTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AGTC alert in real time by email
    SC 13G/A 1 d82338dsc13ga.htm SC 13G/A SC 13G/A
    OMB APPROVAL
    OMB Number:                                3235-0145
    Expires:                                    February 28, 2010
    Estimated average burden
    hours per response                                10.4

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (AMENDMENT NO    7        )*

     

     

    Applied Genetic Technologies Corp

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    03820J 10 0

    (CUSIP Number)

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 7 Pages


    Cusip No. 03820J 10 0    13G    Page 2 of 7 Pages

     

      1       

      NAME OF REPORTING PERSONS

     

      InterWest Partners VIII, LP

     

      I.R.S. IDENTIFICATION NO(S). OF ABOVE PERSON(S) (ENTITIES ONLY)

      2      

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3      

      SEC USE ONLY

     

      4      

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      California

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    REPORTING

    PERSON

    WITH

        5     

      SOLE VOTING POWER

     

      1,404,515

      6     

      SHARED VOTING POWER

     

      0

      7     

      SOLE DISPOSITIVE POWER

     

      1,404,515

      8     

      SHARED DISPOSITIVE POWER

     

      0

      9      

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,404,515

    10      

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11      

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      3.3% (1)

    12      

      TYPE OF REPORTING PERSON

     

      PN

     

    (1)

    Based upon 42,863,552 shares of the Issuer’s Common Stock outstanding as of November 4, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 9, 2021.


    Cusip No. 03820J 10 0    13G    Page 3 of 7 Pages

     

      1       

      NAME OF REPORTING PERSONS

     

      InterWest Management Partners VIII, LLC (the General Partner of InterWest Partners VIII, LP)

     

      I.R.S. IDENTIFICATION NO(S). OF ABOVE PERSON(S) (ENTITIES ONLY)

      2      

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3      

      SEC USE ONLY

     

      4      

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      California

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    REPORTING

    PERSON

    WITH

        5     

      SOLE VOTING POWER

     

      1,404,515

      6     

      SHARED VOTING POWER

     

      0

      7     

      SOLE DISPOSITIVE POWER

     

      1,404,515

      8     

      SHARED DISPOSITIVE POWER

     

      0

      9      

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,404,515

    10      

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11      

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      3.3%(1)

    12      

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    Based upon 42,863,552 shares of the Issuer’s Common Stock outstanding as of November 4, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 9, 2021.


    Cusip No. 03820J 10 0    13G    Page 4 of 7 Pages

     

      1       

      NAME OF REPORTING PERSONS

     

      Gilbert H. Kliman (a Managing Director of InterWest Management Partners VIII, LLC)

     

      I.R.S. IDENTIFICATION NO(S). OF ABOVE PERSON(S) (ENTITIES ONLY)

      2      

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3      

      SEC USE ONLY

     

      4      

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

      BENEFICIALLY  

    OWNED BY

    REPORTING

    PERSON

    WITH

        5     

      SOLE VOTING POWER

     

      1,414,515 (1)

      6     

      SHARED VOTING POWER

     

      0

      7     

      SOLE DISPOSITIVE POWER

     

      1,414,515 (1)

      8     

      SHARED DISPOSITIVE POWER

     

      0

      9      

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,414,515 (1)

    10      

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11      

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      3.3%

    12      

      TYPE OF REPORTING PERSON

     

      IN

    Neither the filing of this statement on Schedule 13G nor any of its contents shall be deemed to constitute an admission by Gilbert H. Kliman that he is the beneficial owner of any of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and such beneficial ownership is expressly disclaimed, except to the extent of his pecuniary interest.

     

    (1)

    Includes 10,000 shares owned directly by Kliman, and 1,404,515 shares owned by IWP VIII.


    Cusip No. 03820J 10 0    13G    Page 5 of 7 Pages

     

    ITEM 1.

     

    (a)

    NAME OF ISSUER: Applied Genetic Technologies Corp.

     

    (b)

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICE:

    14193 NW 119th Terrace, Suite 10, Alachua, Florida 32615

    ITEM 2.

     

    (a)

    NAME OF PERSON(S) FILING:

    InterWest Partners VIII, LP (“IWP VIII”)

    InterWest Management Partners VIII, LLC (“IMP VIII”)

    Gilbert H. Kliman (“Kliman”)

     

    (b)

    ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

    467 First Street, Suite 201, Los Altos, CA 94022

     

    (c)

    CITIZENSHIP/PLACE OF ORGANIZATION:

     

                IWP VIII:    California
       IMP VIII:    California
       Kliman:    United States

     

    (d)

    TITLE OF CLASS OF SECURITIES: Common Stock

     

    (e)

    CUSIP NUMBER: 03820J 10 0

    ITEM 3. NOT APPLICABLE.

    ITEM 4. OWNERSHIP.

     

         IWP VIII      IMP VIII (1)      Kliman (2)  

    Beneficial Ownership

         1,404,515        1,404,515        1,414,515  

    Percentage of Class

         3.3% (3)        3.3% (3)        3.3% (3)  

    Sole Voting Power

         1,404,515        1,404,515        1,414,515  

    Shared Voting Power

         0        0        0  

    Sole Dispositive Power

         1,404,515        1,404,515        1,414,515  

    Shared Dispositive Power

         0        0        0  

     

    (1)

    IMP VIII serves as the general partner of IWP VIII.

    (2)

    Includes 10,000 shares owned directly by Kliman, and 1,404,515 shares owned by IWP VIII. Kliman is the Managing Director of IMP VIII. Beneficial ownership of IWP VIII shares is expressly disclaimed, except to the extent of the pecuniary interest.

    (3)

    Based upon 42,863,552 shares of the Issuer’s Common Stock outstanding as of November 4, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 9, 2021.


    Cusip No. 03820J 10 0    13G    Page 6 of 7 Pages

     

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☒

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    Under certain circumstances set forth in the limited liability company operating agreement of IMP VIII, the members of such limited liability company have the right to receive dividends from, or the proceeds from the sale of, the common stock of Issuer beneficially owned by such limited liability company.

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

    Not applicable.

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    No reporting person is a member of a group as defined in section 240.13d-1(b)(1)(iii)(H) of the Act.

    ITEM 9. NOTICE OF DISSOLUTION OF THE GROUP.

    Not applicable.

    ITEM 10. CERTIFICATION.

    Not applicable.

    EXHIBITS

    Joint Filing Statement attached as Exhibit A.


    Cusip No. 03820J 10 0    13G    Page 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2022

     

    By:  

    /s/ Gilbert H. Kliman

        INTERWEST PARTNERS VIII, LP
    Name:   Gilbert H. Kliman    

     

    By:

     

     

    InterWest Management Partners VIII, LLC

          its General Partner
          By:  

    /s/ Gilbert H. Kliman

           
          INTERWEST MANAGEMENT PARTNERS VIII, LLC
          By:  

    /s/ Gilbert H. Kliman

            Managing Director
    Get the next $AGTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AGTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Applied Genetic Technologies Corporation (Amendment)

      SC 13G/A - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Subject)

      2/14/23 1:22:16 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Applied Genetic Technologies Corporation

      SC 13D - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Subject)

      12/8/22 12:42:24 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Applied Genetic Technologies Corporation

      SC 13G - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Subject)

      11/4/22 4:24:20 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Robinson James A. Jr.

      4 - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Issuer)

      12/1/22 9:23:47 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Vanlent Anne

      4 - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Issuer)

      12/1/22 9:23:04 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Rosen James closing all direct ownership in the company (for withholding tax)

      4 - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Issuer)

      12/1/22 9:22:27 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    Leadership Updates

    Live Leadership Updates

    See more
    • Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer

      Leading Ophthalmologist and Experienced Industry Executive to Advance Development of Innovative Corneal Endothelial Cell Therapy Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Michael Goldstein, M.D., M.B.A., as president and chief medical officer. Dr. Goldstein will lead the Company's clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cell therapy to treat corneal edema secondary to endothelial dysfunction. This press release features multimedia. View the full release here: https://www.businesswire.c

      6/9/22 8:00:00 AM ET
      $AGTC
      $OCUL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors

      GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced the appointment of James Robinson, President and Chief Executive Officer (CEO) of Urovant Sciences, to its Board of Directors. "We are honored to have Jim join our Board of Directors, where his exemplary track record of execution as an executive at leading biotech and pharma companies will b

      12/6/21 8:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer

      With 25+ years of experience, Dr. Scaria has led numerous gene therapy programs from early research into clinical development Dr. Scaria completes a newly expanded management team in place to continue development of late-stage programs in XLRP and Achromatopsia and advance AGTC's preclinical pipeline GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the appointment of Abraham Scaria, Ph.D., as Chief Science Officer. "A gene

      11/16/21 8:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation

      GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), announced today the successful completion of the previously announced tender offer (the "Offer") to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) ("Syncona"). The Offer, as extended, expired at 5:00 p.m., Eastern Time, on November 30, 2022, and the acquisition was completed through a merger under Section 251(h) of the General Corporation Law of the State of Delaware. Pursuant to the terms of the definitive merger agreement, AGTC stockholders are entitled t

      12/1/22 7:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation

      GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) ("Syncona") has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights (CVRs) upon the achievement of specified milestones. The tender offer has been extended until 5:00 p.m., Eastern Time, on November 30, 2022. The tender offer was previously scheduled to exp

      11/29/22 8:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • *FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*

      GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purchase all outstanding shares of AGTC common stock at a price per share of $0.34 in cash plus the right for AGTC stockholders to receive additional aggregate payments of up to $0.73 per share upon the achievement of specified milestones. We urge you to tender your shares in the offer.In order to tender, please contact your bank or broker, or follow the instructions that you previously received by mail or email from

      11/28/22 8:30:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Applied Genetic Technologies Corporation

      15-12G - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Filer)

      12/12/22 8:33:58 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Applied Genetic Technologies Corporation

      EFFECT - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Filer)

      12/7/22 12:15:06 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Applied Genetic Technologies Corporation

      EFFECT - APPLIED GENETIC TECHNOLOGIES CORP (0001273636) (Filer)

      12/7/22 12:15:13 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    Financials

    Live finance-specific insights

    See more
    • Syncona to Acquire Applied Genetic Technologies Corporation

      Upfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC's closing stock price on October 21, 2022 Total consideration of up to $1.07, including up to $0.73 per CVR, representing a premium of up to approximately 344% over AGTC's closing stock price on October 21, 2022 AGTC's Board has examined all alternative options for the future of AGTC and believes this transaction clearly delivers the best value for shareholders Given the state of equity and other funding markets, AGTC sees significant challenges in funding ongoing operations beyond 2022 Syncona and AGTC to host conference call on October 24, 2022 at 7:30 a.m. ET

      10/23/22 10:05:16 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa

      – 62.5% of Patients in Dose Group B Were Responders for Improvements in Visual Sensitivity, the Study's Primary Efficacy Endpoint – – Continued Strong Safety Data – – Robust Safety and Efficacy Data Consistent with Previously Reported Results from the Phase 1/2 Trial in XLRP – – Company to Host Conference Call to Review Data on May 17 at 8:00 a.m. ET – GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited ret

      5/16/22 4:01:00 PM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021

      -Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced financial results for the quarter ended December 31, 2021. "We enter 2022 with significant momentum from the recent buildout of our management team

      2/14/22 7:00:00 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG initiated coverage on Applied Genetic with a new price target

      BTIG initiated coverage of Applied Genetic with a rating of Buy and set a new price target of $11.00

      6/15/21 6:43:59 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stifel Nicolaus initiated coverage on Applied Genetic Technologies with a new price target

      Stifel Nicolaus initiated coverage of Applied Genetic Technologies with a rating of Buy and set a new price target of $14.00

      3/8/21 8:22:11 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stifel initiated coverage on Applied Genetic Technologies with a new price target

      Stifel initiated coverage of Applied Genetic Technologies with a rating of Buy and set a new price target of $14.00

      3/2/21 6:25:42 AM ET
      $AGTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care